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Identity 
Other names: EDG2; GPR26; LPA-1; LPA1; 
Mrec1.3; VZG1; edg-2; rec.1.3; vzg-1 








LPAR1 is an abbreviation for the LPA1 receptor, the 
first receptor cloned and identified from a growing 
number of LPA receptors that includes the Edg-family 
and the purinergic receptors. 
Expression 
LPAR1 is ubiquitously expressed throughout cells and 
tissues in the body. 
High level of expression is found in amygdale,  
 
Figure of the LPAR1, a G protein-coupled receptor, spanning the plasma membrane seven times. The receptor has three numbered 
extracellular and intracellular loops that are involved in signal transduction. Also shown are the amino terminus and carboxyl terminal tail. 
Three regions of the carboxyl terminal tail have been shown to be important for the LPAR1 signaling and receptor regulation. LPAR1 
contains a canonical Type 1 PDZ binding domain (a.a. 362-364) at the extreme C-terminus. This domain has been shown to be required 
for LPA-induced cell proliferation and activation of Rho family GTPases via PDZ-Rho guanine nucleotide exchange factors. Further 
upstream in the carboxyl terminal tail, LPAR1 contains a di-leucine sequence (a.a. 351 and 352), which is required for phorbol ester-
induced internalization. Still further upstream lies a serine-rich cluster (a.a. 341-347) that is required for beta-arrestin association, which is 
critical for signal attenuation and receptor endocytosis. 
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prefrontal cortex, caudate nucleus, hypothalamus, 
medulla oblongata, olfactory bulb, parietal lobe, spinal 
cord and thalamus. 
Moderately high level of expression is found in 
adipocytes, cingulated cortex, occipital lobe, pons, 
whole brain, globus pallidus, subthalamic nucleus, 
temporal lobe, appendix, monocytes and smooth 
muscle. 
Slightly above median level of expression is found in 
bronchial epithelial cells, cerebellum peduncies, dorsal 
root ganglia, ciliary ganglion, uterus, uterus corpus, 
atrioventricular node, fetal lung, fetal thyroid, skeletal 
muscle, cardiac myocytes, salivary gland, tongue and 
lymph node. It is also expressed in tissues during 
neuronal development. The expression of LPAR1 is 
increased in blister skin compared to normal skin. The 
mRNA of LPAR1 is significantly increased 8 days after 
unilateral uretheral obstruction in mice kidneys where 
expression is higher in the medulla than the cortex. The 
expression of LPAR1 is variable in cancer. 
Localisation 
It is a requirement of G protein-coupled receptor 
functioning that receptors are embedded into 
membranes for proper structure. The LPAR1 spans the 
plasma membrane seven times in a barrel conformation 
with three extracellular and three intracellular loops. At 
steady state, LPAR1 is located on the plasma 
membrane at the cell surface until it binds LPA, which 
triggers dynamin2-dependent, clathrin-mediated 
endocytosis into the cell. LPAR1 requires membrane 
cholesterol for association with beta-arrestin, which 
targets the receptor to clathrin-coated pits for 
internalization. In addition to LPA, phorbol ester 
stimulation of protein kinase C also induces 
internalization of LPAR1, but this does not require 
beta-arrestin. Rather, phorbol ester-dependent 
internalization of LPAR1 requires AP-2 clathrin 
adaptors. The LPAR1 is subsequently sorted through 
Rab-5 dependent early and recycling endosomes before 
it is recycled back to the cell surface or degraded in 
lysosomes. 
The receptor may also be localized to the nuclear 
membrane in the cell. Some evidence indicates that a 
portion of the total cellular LPAR1 localizes to the 
nuclear membrane in PC12 cells, micro-vascular 
endothelial cells, and human bronchial epithelial cells. 
The exact function of this nuclear LPAR1 pool is not 
known. 
Function 
The LPAR1 binds LPA and initiates G protein-
dependent signal transduction cascades throughout the 
cell that result in a number of functional outcomes, 
depending on the specific cell or tissue type. The G 
alpha proteins involved are Gi, Gq and G 12/13. The 
receptor has critical functions that have been elucidated 
through gene knock-out studies in mice. LPAR1-null  
mice have deficiencies in olfactory development that 
impairs their ability to locate maternal nipples and 
initiate suckling required for survival. The lack of 
olfactant detection leads to 50% lethality among pups. 
Other LPAR1-null mice demonstrate alterations in 
neurotransmitters that mimic models of schizophrenia. 
LPAR1-null mice are 10-15% shorter than wild-type 
mice and have gross anatomical defects due to bone 
development, including incisor overgrowth that affects 
ability to feed. The LPAR1 functions in normal cortical 
development and commits cortical neuroblasts to 
differentiate through the neural lineage. It may also 
play a role in the formation of dendritic spine synapses. 
Through autotoxin-generated LPA, LPAR1 mediates 
neuropathic pain induced by nerve injury. Activation of 
the LPAR1 functions in the inflammatory response; 
receptor activation stimulates the recruitment of 
macrophages. 
The LPAR1 positively regulates motility in a variety of 
cell types, exerting a dominant signal in the absence of 
LPAR4. 
Homology 
The LPAR1 has significant homology with LPAR2 
(57%) and LPAR3 (51%), members of the original or 
classical endothelial differentiation gene (Edg) family. 
It has approximately 33-38% homology with individual 
sphingosine 1-phosphate receptors and no significant 
homology with the purinergic family of receptors that 
also bind LPA. 
Mutations 
Note 
There are several single nucleotide polymorphisms 
(SNPs) reported within the LPAR1 gene and several of 
these are associated with altered phenotype and disease 
states. 
A functional SNP located in the promoter region of the 
gene (-2,820G/A; rs10980705) is associated with 
increased susceptibility to knee osteoarthritis in 
Japanese by showing an increase in binding and 
activity. 
A change in amino acid sequence at position 125 from 
glutamine to glutamate in the LPAR1 will result in the 
ability of the receptor to recognize both S1P and LPA. 
A change in amino acid sequence at position 236 from 
threonine to lysine in the LPAR1 will result in the 
enhanced activation of serum response factor. 
Mutations in the LPAR1 were detected in a small 
percentage of adenomas and adenocarcinomas of rats 
given BHP in their drinking water. Missense mutations 
in the LPAR1 were detected in rat hepatocellular 
carcinomas induced by N-nitroso-diethylamine and 
choline-deficient l-amino acid-defined diets. 
Deletion of the PDZ domain of the receptor prevents 
signal attenuation that controls LPA-mediated receptor 
activation and cell proliferation. 
 










Overexpression of the LPAR1 in mice contributes to 
the tumorigenicity and aggressiveness of ovarian 
cancer. 
Prognosis 
Upregulation of the LPAR1 appears to enhance tumor 
progression in the previous examples. 
Oncogenesis 
The LPAR1 is a proto-oncogene contributing to the 
metastatic potential of breast cancers and may require 
signals from ErbB2/HER2 dimerization. In a study 
designed to assess the functional conseq-uences of 
overexpression as it relates to breast carcinogenesis, 
1000 selected/suspected cDNAs were inserted into 
immortalized MCF-10A cells and a derivative cell line, 
MCF-10A.B2 expressing an inducibly active variant of 
ErbB2. The study examined three assays (cell 
proliferation, migration and 3-D matrigel acinar 
morphogenesis) and the LPAR1 scored positive in all 
three; thus, it was determined to be a proto-oncogene in 
this disease. Several observations are of interest: first, 
the LPAR1 induced migration in the absence of ErbB2 
activation but not in the absence of dimerization which 
suggests that the LPAR1 may require weak signals 
from ligand-independent dimerization of ErbB2 to 
induce migration; second, in the acinar morphogenesis 
assay, phenotypical changes of cells with the LPAR1 
included the formation of features of invasive tumor 
cells, such as disorganized acinar structure, large 
structures and protrusive behavior; third, the LPAR1 
was capable of establishing abnormal 3-D 




The LPAR1 mediates fibroblast migration and 
recruitment in the injured lung. The chemotactic 




The concentration of LPA is elevated in broncho-
alveolar lavage samples from patients with idio-pathic 
pulmonary fibrosis. The fibroblasts of these patients 
require expression of LPAR1 for the chemotactic 
activity present in this pathology. Data suggests that 
LPAR1-null mice are substantially protected from 
fibroblast accumulation. This corresponds to lung 
injury where aberrant wound-healing responses 
exacerbate pulmonary fibrosis pathogenesis. 
Prognosis 
LPAR1 links lung injury with pulmonary fibrosis 
development. 
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